Jason P Sinnwell
Overview
Explore the profile of Jason P Sinnwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Comba I, Mars R, Yang L, Dumais M, Chen J, Van Gorp T, et al.
bioRxiv
. 2024 Dec;
PMID: 39713288
Long COVID (LC), manifests in 10-30% of non-hospitalized individuals post-SARS-CoV-2 infection leading to significant morbidity. The predictive role of gut microbiome composition during acute infection in the development of LC...
2.
Schaid D, McDonnell S, Akhtari F, Sinnwell J, Batzler A, Cobran E, et al.
HGG Adv
. 2024 Nov;
6(1):100389.
PMID: 39604263
The use of polygenic scores (PGS) for personalized medicine has gained momentum, along with caution to avoid accentuating health disparities. Greater ancestral diversity in genetic studies is needed, as well...
3.
Leon-Ferre R, Carter J, Zahrieh D, Sinnwell J, Salgado R, Suman V, et al.
NPJ Breast Cancer
. 2024 Mar;
10(1):25.
PMID: 38553444
Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide...
4.
Stan D, Kim J, Schaid D, Carlson E, Kim C, Sinnwell J, et al.
Cancer Prev Res (Phila)
. 2023 Dec;
17(2):77-84.
PMID: 38154464
Prevention Relevance: Risk-reducing medications for breast cancer are considerably underused. Informing women at risk with precise and individualized risk assessment tools may substantially affect the incidence of breast cancer. In...
5.
Tang X, Thompson K, Kalari K, Sinnwell J, Suman V, Vedell P, et al.
Breast Cancer Res
. 2023 May;
25(1):57.
PMID: 37226243
Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions...
6.
Sicotte H, Kalari K, Qin S, Dehm S, Bhargava V, Gormley M, et al.
Mol Cancer Res
. 2022 Sep;
20(12):1739-1750.
PMID: 36135372
Implications: Finally, we identified candidates drugs to reverse AA/P resistance: topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K_AKT_MTOR pathways.
7.
Thompson K, Leon-Ferre R, Sinnwell J, Zahrieh D, Suman V, Metzger F, et al.
NAR Cancer
. 2022 Jun;
4(2):zcac018.
PMID: 35734391
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor...
8.
Macauda A, Clay-Gilmour A, Hielscher T, Hildebrandt M, Kruszewski M, Orlowski R, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Jun;
31(9):1863-1866.
PMID: 35700034
Background: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have...
9.
Schaid D, Sinnwell J, Batzler A, McDonnell S
Am J Hum Genet
. 2022 Mar;
109(5):900-908.
PMID: 35353984
Polygenic risk scores (PRSs) for a variety of diseases have recently been shown to have relative risks that depend on age, and genetic relative risks decrease with increasing age. A...
10.
Vachon C, Murray J, Allmer C, Larson D, Norman A, Sinnwell J, et al.
Blood Adv
. 2022 Mar;
6(12):3746-3750.
PMID: 35316833
Mass-spectrometry (MS) assays detect lower levels of monoclonal proteins and result in earlier detection of monoclonal gammopathy of undetermined significance (MGUS). We examined heavy chain MGUS prevalence using matrix-assisted laser...